Jiang Longying, Zhang Huajun, Xiao Desheng, Wei Hudie, Chen Yongheng
Department of Pathology, NHC Key Laboratory of Cancer Proteomics, Laboratory of Structural Biology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Laboratory of Structural Biology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Comput Struct Biotechnol J. 2021 Apr 20;19:2148-2159. doi: 10.1016/j.csbj.2021.04.029. eCollection 2021.
Farnesoid X receptor (FXR) is a bile acid activated nuclear receptor (BAR) and is mainly expressed in the liver and intestine. Upon ligand binding, FXR regulates key genes involved in the metabolic process of bile acid synthesis, transport and reabsorption and is also involved in the metabolism of carbohydrates and lipids. Because of its important functions, FXR is considered as a promising drug target for the therapy of bile acid-related liver diseases. With the approval of obeticholic acid (OCA) as the first small molecule to target FXR, many other small molecules are being evaluated in clinical trials. This review summarizes the structures of FXR, especially its ligand binding domain, and the development of small molecules (including agonists and antagonists) targeting FXR.
法尼酯X受体(FXR)是一种胆汁酸激活的核受体(BAR),主要在肝脏和肠道中表达。在配体结合后,FXR调节参与胆汁酸合成、转运和重吸收代谢过程的关键基因,还参与碳水化合物和脂质的代谢。由于其重要功能,FXR被认为是治疗胆汁酸相关肝病的一个有前景的药物靶点。随着奥贝胆酸(OCA)作为首个靶向FXR的小分子药物获批,许多其他小分子正在临床试验中进行评估。本综述总结了FXR的结构,尤其是其配体结合结构域,以及靶向FXR的小分子(包括激动剂和拮抗剂)的研发情况。